saratin

a recombinant protein, isolated from the saliva of the leech Hirudo medicinalis; a potent inhibitor of vWF-dependent platelet adhesion to collagen and hence may have therapeutic potential as an antithrombotic agent

Networked: 7 relevant articles (2 outcomes, 3 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Levine, Monica A: 3 articles (01/2015 - 01/2012)
2.	Lukowski, Zachary L: 3 articles (01/2015 - 01/2012)
3.	Meyers, Craig A: 3 articles (01/2015 - 01/2012)
4.	Min, Jeff: 3 articles (01/2015 - 01/2012)
5.	Schultz, Gregory S: 3 articles (01/2015 - 01/2012)
6.	Sherwood, Mark B: 3 articles (01/2015 - 01/2012)
7.	Beattie, Ashley R: 2 articles (11/2012 - 01/2012)
8.	Samuelson, Don A: 2 articles (11/2012 - 01/2012)
9.	Brown, Aliza T: 2 articles (12/2004 - 07/2003)
10.	Cruz, Carlos P: 2 articles (12/2004 - 07/2003)

Related Diseases

1.	Hyperplasia 07/01/2003 - "Intimal hyperplasia normalized to vein wall thickness also showed a significant reduction with saratin application. " 07/01/2003 - "In the current study, the authors investigated the effects of topical saratin administration in a canine dialysis access model in regard to intimal hyperplasia development at the venous anastomosis. " 12/01/2004 - "Intimal hyperplasia: 5.0 microg Saratin in the HCys group decreased intimal hyperplasia by 45% compared with the non-Saratin-treated HCys group. " 07/01/2003 - "Saratin provides for a method of substantially reducing intimal hyperplasia by direct local application without systemic side effects." 07/01/2003 - "Distribution of intimal hyperplasia by blocks between control and saratin groups were as follows: block [A] 8.6 +/- 1.9 vs 9.7 +/- 3.0% (p=NS), [B] 32.7 +/- 6.3 vs 10.7 +/- 3.5% (p=0.01), [C] 44.8 +/- 6.2% vs 10.3 +/- 1.5% (p=0.0004), [D] 40.8 +/- 11.0 vs 9.1 +/- 4.2% (p=0.02), [E] 7.5 +/- 5.5 vs 2.7 +/- 0.4% (p=NS). "
2.	Blister (Bulla) 11/19/2012 - "A single postoperative injection of saratin was able to prolong the duration of bleb elevation when compared to BSS controls. " 01/01/2012 - "Rabbits receiving saratin did not develop bleb avascularity and thinning associated with MMC treatment and there were no apparent clinical signs of toxicity. " 01/01/2012 - "Rabbits receiving topical+injections of saratin had a mean bleb survival of 33.6±8.5 days, significantly higher than the negative BSS controls, which averaged 17.4±6.0 days (p = 0.018). " 11/19/2012 - "Rabbits receiving only one perioperative saratin injection had a mean bleb survival time of 29.8 ± 5.3 days, while those receiving multiple (either 3 or 5+) injections of saratin had mean bleb survival times of 26.3 ± 8.1 and 26.4 ± 4.2 days, respectively. " 01/01/2012 - "The goal of this study was to compare the efficacy of saratin with that of the widely accepted mitomycin-C (MMC) in prolonging bleb survival following GFS in the rabbit model. "
3.	Glaucoma 11/19/2012 - "We compared the anti-fibrotic effects of single versus multiple postoperative injections of saratin following glaucoma filtration surgery (GFS) in the rabbit model. " 01/01/2012 - "The protein saratin has been shown to exhibit anti-fibrotic and anti-thrombotic properties in response to injury, but had not been used for glaucoma surgery. " 01/01/2012 - "Prevention of ocular scarring post glaucoma filtration surgery using the inflammatory cell and platelet binding modulator saratin in a rabbit model." 01/01/2015 - "Sequential Therapy with Saratin, Bevacizumab and Ilomastat to Prolong Bleb Function following Glaucoma Filtration Surgery in a Rabbit Model." 01/01/2015 - "To determine if sequential treatment with Bevacizumab (Avastin), a monoclonal, VEGF antibody that blocks angiogenesis; Saratin, a 12 kD polypeptide with anti-inflammatory and anti-thrombotic properties; and Ilomastat, a matrix metalloproteinase (MMP) inhibitor, prolongs bleb life following glaucoma filtration surgery (GFS) in a rabbit model. "
4.	Pathologic Constriction (Stenosis) 12/01/2004 - "Saratin significantly inhibited platelet adhesion at > or =5.0 microg, and Saratin at 5.0 microg attenuated luminal stenosis in a hyperhomocysteinemic rat CEA model." 10/01/2001 - "A percent luminal stenosis, as a measure of intimal hyperplasia, was significantly decreased with saratin application compared with controls (10.9% +/- 1.8% vs 29.8% +/- 6.8%, P = .0042). " 10/01/2001 - "Saratin significantly decreased platelet adhesion, intimal hyperplasia, luminal stenosis, and thrombosis after carotid endarterectomy in rats. "
5.	Atherosclerotic Plaque (Atheroma) 07/01/2004 - "These results suggest that the local site-specific treatment with saratin inhibits atherosclerotic plaque thrombogenicity at haemodynamic conditions typical of moderately stenotic coronary arteries." 07/01/2004 - "Under stenotic shear conditions of 800/s, saratin significantly (p<0.05) reduced platelet deposition triggered by human denuded vessel wall (44%), fatty streaks (47%), severely damaged vessel (50%) and atherosclerotic plaque (57%). " 07/01/2004 - "Antithrombotic effects of saratin on human atherosclerotic plaques."

Related Drugs and Biologics

1.	Mitomycin (Mitomycin-C)
2.	Collagen
3.	Proteins (Proteins, Gene)
4.	Phenobarbital (Luminal)
5.	Matrix Metalloproteinase Inhibitors
6.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
7.	Matrix Metalloproteinases (MMPs)
8.	von Willebrand Factor
9.	Polytetrafluoroethylene (Teflon)
10.	Peptides (Polypeptides)

Related Therapies and Procedures

1.	Carotid Endarterectomy
2.	Filtering Surgery
3.	Therapeutics
4.	Sutures (Suture)
5.	Injections